2022
Clinical outcomes following dalbavancin administration in patients with barriers to outpatient parenteral antimicrobial therapy
Tuan J, Kayani J, Fisher A, Kotansky B, Dembry L, Datta R. Clinical outcomes following dalbavancin administration in patients with barriers to outpatient parenteral antimicrobial therapy. Antimicrobial Stewardship & Healthcare Epidemiology 2022, 2: e83. PMID: 36483361, PMCID: PMC9726471, DOI: 10.1017/ash.2022.229.Peer-Reviewed Original ResearchDalbavancin administrationOutpatient parenteral antimicrobial therapyDose of dalbavancinMedian antibiotic durationSoft tissue infectionsParenteral antimicrobial therapyAntibiotic durationDeveloped hepatotoxicityClinical cureSeptic arthritisClinical outcomesAntimicrobial therapyPatientsAdministrationDaysEndocarditisArthritisBacteremiaOsteomyelitisHepatotoxicityTherapyDalbavancinInfectionDose
2019
Antimicrobial therapy for asymptomatic bacteriuria or candiduria in advanced cancer patients transitioning to comfort measures
Datta R, Wang T, Zhu M, Dembry LM, Han L, Allore H, Quagliarello V, Juthani-Mehta M. Antimicrobial therapy for asymptomatic bacteriuria or candiduria in advanced cancer patients transitioning to comfort measures. Infection Control And Hospital Epidemiology 2019, 40: 470-472. PMID: 30821230, PMCID: PMC6482377, DOI: 10.1017/ice.2019.22.Peer-Reviewed Original ResearchConceptsUrinary tract infectionIncidence rate ratiosAdvanced cancer patientsAsymptomatic bacteriuriaCancer patientsAntimicrobial therapySymptomatic urinary tract infectionPotential urinary tract infectionTract infectionsInappropriate therapyAntimicrobial daysComfort measuresBacteriuriaCandiduriaCFU/mLPatientsTherapyRate ratioMLInfection
2007
Trends in Prescribing β-Lactam Antibiotics for Treatment of Community-Associated Methicillin-Resistant Staphylococcus aureus Infections
Gupta K, MacIntyre A, Vanasse G, Dembry LM. Trends in Prescribing β-Lactam Antibiotics for Treatment of Community-Associated Methicillin-Resistant Staphylococcus aureus Infections. Journal Of Clinical Microbiology 2007, 45: 3930-3934. PMID: 17942648, PMCID: PMC2168566, DOI: 10.1128/jcm.01510-07.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAnti-Bacterial AgentsBeta-LactamsChildChild, PreschoolCommunity-Acquired InfectionsDrug PrescriptionsFemaleHealth Services ResearchHumansInfantInfant, NewbornMaleMethicillin ResistanceMiddle AgedPrevalenceStaphylococcal InfectionsStaphylococcus aureusUnited StatesConceptsCA-MRSA soft tissue infectionsSoft tissue infectionsInitial empirical therapyCA-MRSA isolatesEmpirical therapyAntimicrobial therapyCommunity-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) isolatesStaphylococcal chromosomal cassette mec type IVS. aureus soft tissue infectionsResistant Staphylococcus aureus infectionsMethicillin-Resistant Staphylococcus aureus IsolatesInactive antimicrobial therapyRate of prescribingCA-MRSA infectionsInitial antimicrobial therapyMajority of patientsMedical record reviewSubset of patientsCommunity-Associated MethicillinStaphylococcus aureus infectionPanton-Valentine leukocidinStaphylococcus aureus isolatesBeta-lactam antibioticsDiscordant therapyRate of use